CRMD CorMedix Inc. Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
16:48
Jan 14
Jan 14
CRMD cheap value play, 2026 Phase 3 catalyst
The author calls CorMedix a buy-and-hold value play, citing a trailing PE of 3 and a Phase 3 readout for an additional indication due late 2026. He notes a big gap down on a flat 2026 revenue forecast and suggests a potential entry at $5.60 or less while support sits near $7 with moving averages trending down. He explicitly says buy at your own risk.
HIGH
09:13
Jan 12
Jan 12
Author aggressively buys ahead of CEO presentation.
Author discloses aggressive buying of the stock, citing an attractive risk/reward profile following deep research and an upcoming CEO presentation.
MED
10:51
Jan 09
Jan 09
Technical payment issue masks strong future pricing.
Author contends the projected 2026 decline is merely a technical payment issue, with fair reimbursement and pricing power returning in 2027.
MED
10:51
Jan 09
Jan 09
Stock price incorrectly discounts post-2027 forecast.
Author argues the current stock price incorrectly discounts management's post-2027 forecast, which is a mathematically inevitable outcome of recent sales.
MED
07:39
Jan 09
Jan 09
Market ignores Rezzayo's $2B market potential.
Author highlights Needham's Buy rating and argues that the market is currently assigning zero value to Rezzayo's $2B market potential.
MED
07:39
Jan 09
Jan 09
RBC rates Outperform with $22 target.
Reports RBC rating Outperform with a $22 price target, citing sandbagged guidance and clinical superiority.
MED
15:13
Jan 08
Jan 08
Author enters long for upside potential.
Author discloses a new long position, citing an attractive business with significant upside potential at 8-10x EV/FCF.
MED
14:28
Jan 08
Jan 08
Attractive valuation with highly conservative guidance.
Valuation is attractive at 8-10x EV/FCF with conservative guidance that completely disregards the pipeline and new customers.
MED
15:08
Nov 12
Nov 12
Notes wild intraday swings following earnings reports.
Observes wild intraday price swings following earnings reports, noting market hysteria without a directional view.
LOW
06:16
Sep 25
Sep 25
Discloses large existing positions and recent additions
Author discloses large existing positions and recent additions across these names in a monthly portfolio update.
MED
16:10
Sep 18
Sep 18
Buys shares citing strong future cash flow
Author bought shares, citing a high likelihood of generating $1B in free cash flow by 2032 compared to a current $900M market cap.
MED
About CRMD Investor Commentary
Across the available history and selected sources, Buzzberg tracks CRMD (CorMedix Inc.) across 2 sources: 1 bullish vs 0 bearish calls from 2 authors. Historical directional balance: 9% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 11 total trade ideas tracked. Latest voices: u/12HAMMER-U, @MoodyWriter13, moodywriter13.